AEP
40
-2
LRCX
45
2
EQR
37
-5
IVZ
52
6
WAT
55
24
BBY
40
2
KMB
33
2
MMM
30
-3
EXR
46
-2
SPG
48
-5
ADI
49
3
PEG
44
-2
NTRS
49
-3
FSLR
57
8
ABT
62
9
WFC
71
-3
YUM
38
2
GLW
52
2
MOS
42
2
MA
58
3
AEP
40
-2
LRCX
45
2
EQR
37
-5
IVZ
52
6
WAT
55
24
BBY
40
2
KMB
33
2
MMM
30
-3
EXR
46
-2
SPG
48
-5
ADI
49
3
PEG
44
-2
NTRS
49
-3
FSLR
57
8
ABT
62
9
WFC
71
-3
YUM
38
2
GLW
52
2
MOS
42
2
MA
58
3
Financhill
Back

Amylyx Pharmaceuticals 10K Form

Sell
45

AMLX
Amylyx Pharmaceuticals

Last Price:
5.72
Seasonality Move:
6.44%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive AMLX News And Ratings

See the #1 stock for the next 7 days that we like better than AMLX

AMLX Financial Statistics

Sales & Book Value

Annual Sales: $380.79M
Cash Flow: $-66.67M
Price / Cash Flow: 0
Annual Sales: $3.84
Price / Book: 1.47

Profitability

EPS (TTM): -2.45000
Net Income (TTM): $-165.87M
Gross Margin: $355.35M
Return on Equity: -45.47%
Return on Assets: -37.92%

Amylyx Pharmaceuticals Earnings Forecast

Key Amylyx Pharmaceuticals Financial Ratios

  • The Gross Profit Margin over the past 3 years for AMLX is 93.32%.
  • The Selling, General & Administrative Expenses for AMLX have been equal to 49.47% of Gross Profit Margin.
  • The Research & Development expenses have been 33.66% of Revenue.
  • The Interest Expense is 0.00% of Operating Income.
  • Per Share Earnings over the last 5 years have been positive in 1 years.

Amylyx Pharmaceuticals Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: AMLX
Website: amylyx.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 4.66
Quick Ratio: 4.48

Price-to-Earnings

Trailing P/E Ratio: 8.06
Forward P/E Ratio: 0

AMLX Technical Analysis vs Fundamental Analysis

Sell
45
Amylyx Pharmaceuticals (AMLX) is a Sell

Is Amylyx Pharmaceuticals a Buy or a Sell?